Results 41 to 50 of about 565 (91)

Long noncoding RNA NR2F1-AS1 enhances the malignant properties of osteosarcoma by increasing forkhead box A1 expression via sponging of microRNA-483-3p. [PDF]

Aging (Albany NY), 2019
The long noncoding RNA NR2F1-AS1 has been found to promote the development of hepatocellular carcinoma and endometrial cancer. In this study, we measured NR2F1-AS1 expression in osteosarcoma (OS), determined the involvement of NR2F1-AS1 in the malignant properties of OS, and investigated the underlying mechanisms.
Li S, Zheng K, Pei Y, Wang W, Zhang X.
europepmc   +3 more sources

Retraction of: Long noncoding RNA NR2F1-AS1 promotes the malignancy of non-small cell lung cancer via sponging microRNA-493-5p and thereby increasing ITGB1 expression. [PDF]

Aging (Albany NY)
Zhang C, Wu S, Song R, Liu C.
europepmc   +2 more sources

Long non-coding RNA NR2F1-AS1 promoted neuroblastoma progression through miR-493-5p/TRIM2 axis.

European review for medical and pharmacological sciences, 2020
Long noncoding RNA (lncRNA) plays a vital role in the progression of various cancers. However, the potential mechanisms of NR2F1-AS1 in the tumorigenesis of neuroblastoma (NB) have not been determined.The expression levels of NR2F1-AS1, miR-493 and TRIM2 were detected by RT-qPCR.
Liu, L., Zhao, H., He, H.-H., Huang, J., Xu, Y.-Y., Li, X.-L., Wu, Y., Wang, J., Zhu, Y.-B.   +8 more
openaire   +2 more sources

Multidisciplinary Strategies for Targeting Tumor Dormancy in Breast Cancer Therapeutics: Hallmarks, Mechanism, and Approaches

iMetaMed, Volume 2, Issue 2, June 2026.
Clinical phases and classification of breast tumor dormancy. Tumor dormancy is described as the period after treatment until residual tumor cells become detectable as relapsing disease in clinic. During the period of clinical tumor dormancy, tumor mass dormancy and cellular dormancy may coexist.
Shu Chen, Hui Chen, Vijaya Raghavan, Jing Huang, Jin Wang   +4 more
wiley   +1 more source

RNA Modifications: Current Understandings and Future Perspectives

MedComm, Volume 7, Issue 5, May 2026.
Types of RNA modification. We have summarized the currently common types of RNA modifications, including ac4C, m6A, m1A, m5C, m3C, m7G, and ψ, and visually characterized their features through structural formulas. The characteristic structures are marked with a background color different from the background color.
Shiyu Xiao, Tingwen Xiang, Chuan Yang, Xiaohua Wang, Gang Huang, Fei Luo, Zhao Xie, Yueqi Chen   +7 more
wiley   +1 more source

Targeting Tumor Dormancy and Recurrence: Molecular Mechanisms and Peptide Therapeutic Delivery

MedComm – Oncology, Volume 5, Issue 1, March 2026.
This review summarizes the molecular mechanisms that regulate tumor dormancy and its role in cancer recurrence, with emphasis on immune evasion, extracellular matrix remodeling, metabolic regulation and angiogenic switching. It further discusses emerging peptide–based therapeutic strategies aimed at detecting, modulating, and eliminating dormant tumor ...
Abdur Raheem Aleem, Atif Ali, Wajid Ali, Yuying Cheng, Zhibin Yan, Chaoyi Xia, Chenguang Liu, Caiyun Fu, Yiren Hu, Xi Wang   +9 more
wiley   +1 more source

Targeted Therapies in the Most Common Advanced Solid Tumors, Drug Resistance, and Counteracting Progressive Micrometastatic Disease: The Next Frontier of Research

MedComm, Volume 6, Issue 10, October 2025.
In TME, undetectable DCCs (panel A) join with a low tumor burden along with low immune suppression, that favor successful immune manipulation through immune suppression inhibiting immune‐therapy. This moves the immune balance toward the immune response and likely makes more stable the dormant state of DCCs in the unstable metastatic niche and/or allows
Andrea Nicolini, Paola Ferrari, Roberto Silvestri, Dario A. Bini   +3 more
wiley   +1 more source

Copy number variations contribute to malignant tumor development in children with serious birth defects

Molecular Oncology, Volume 19, Issue 3, Page 899-912, March 2025.
Children with birth defects are more likely to develop cancer. We observed strong heterogeneity and uneven distributions of copy number variations (CNVs) in 454 such children, with limited occurrence of cancer predisposition genes. However, consistency of the functional impact of CNVs on pathways, and enrichment of non‐coding RNA, was observed, showing
Yichuan Liu, Joseph Glessner, Hui‐Qi Qu, Xiao Chang, Haijun Qiu, Tiancheng Wang, Frank D. Mentch, Hakon Hakonarson   +7 more
wiley   +1 more source

Genome‐wide profiling of N6‐methyladenosine‐modified pseudogene‐derived long noncoding RNAs reveals the tumour‐promoting and innate immune‐restraining function of RPS15AP12 in ovarian cancer

Clinical and Translational Medicine, Volume 15, Issue 3, March 2025.
Genome‐wide profiling reveals the redistribution of m6A modification on pseudogene‐derived lncRNAs and m6A redistribution‐relevant dysregulation of pseudogenes in HGSOC. RPS15AP12, as a representative processed pseudogene, is up‐regulated by FTO‐mediated demethylation and acts as a miRNA sponge to promote RPS15A expression via competitively binding to ...
Jie Xu, Yifei Ren, Jiayi Lu, Fengjiang Qin, Dan Yang, Chunyan Tang, Yu Yang, Jing Xu, Tao Liu, Ping Yi   +9 more
wiley   +1 more source

LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363.

J Cell Mol Med, 2018
AbstractEmerging evidence has validated the vital role of long non‐coding RNA (lncRNA) in the chemoresistance of cancer treatment. In the present study, we investigate the function of lncRNA NR2F1‐AS1 on oxaliplatin (OXA) resistance of hepatocellular carcinoma (HCC) and discover the underlying molecular mechanism. Results revealed that lncRNA NR2F1‐AS1
Huang H, Chen J, Ding CM, Jin X, Jia ZM, Peng J.   +5 more
europepmc   +3 more sources